Novo Nordisk has completed its acquisition of Dicerna Pharmaceuticals, Inc (NASDAQ: DRNA). The deal was previously announced November 18, 2021.

Novo will acquire all outstanding shares of Dicerna common stock for a price of $38.25 per share. Following the tender offer, the deal was completed through a merger of Novo’s wholly owned subsidiary with Dicerna where all non-tendered shares were cancelled and converted to right to receive cash equal to the tender price.

Novo is a global healthcare company focused on defeating diabetes and other chronic illnesses including obesity, rare blood and endocrine disorders. The firm employs 47,000 people across 80 countries.